| 王月兴邓丽娟△ 郭豫兰邓旭曾凡清胡静.肝癌患者经系统治疗后甲胎蛋白变化对预后的影响[J].,2012,12(2):293-294 |
| 肝癌患者经系统治疗后甲胎蛋白变化对预后的影响 |
| Prognostic Influence of Changes of Alpha-Fetoprotein in Patientsreceiving Systemic Therapy with Hepatocellular Carcinoma |
| |
| DOI： |
| 中文关键词: 肝癌 系统治疗 甲胎蛋白 预后 |
| 英文关键词: Hepatocellular carcinoma Systemic therapy Alpha-fetoprotein Prognosis |
| 基金项目: |
|
| 摘要点击次数: 659 |
| 全文下载次数: 1022 |
| 中文摘要: |
| 目的：探讨肝癌患者经系统治疗后甲胎蛋白（AFP）变化对患者预后的影响。方法：对53 例肝癌患者于入院后和系统治疗后
分别于不同时间点测定血清AFP 值后，将入院时AFP 值作为基线，以变化50%作为标准分组，并进行无疾病进展生存时间（PFS）
和总生存时间（OS）分析。结果：9 例患者血清AFP 值下降超过50%（A 组），28 例患者AFP 值升高超过50%（B 组），而AFP 值变
化小于50%（C 组）的为16 例。和C 组相比，A 组患者PFS 明显延长（P＜0.05），B 组PFS 明显缩短（P＜0.05）。B 组OS 短于C 组
（P＜0.01），而A 组和C 组间OS 无明显差别（P＞0.05）。结论：肝癌系统治疗前后的AFP 值变化可作为临床上预后判断的标志之
一。 |
| 英文摘要: |
| Objective: To explore the prognostic influence of the changes of alpha-fetoprotein in patients receiving systemic therapy
with hepatocellular carcinoma. Methods: Serum AFP was collected at baseline and at different time points after admission receiving systemic
therapy in 53 patients with hepatocellular carcinoma. Patients were separated into different groups based on a 50% change in serum
AFP from baseline. Overall survival (OS), progression-free survival (PFS) were compared between groups. Results: Nine patients experienced
a >50% AFP decline(Group A), 28 patients had a>50%AFP increase(Group B), and 16 patients had a <50% change in serum AFP
in either direction (Group C).Compared with Group C, Group A had a longer PFS time (P＜0.05), whereas Group B had a shorter PFS
time (P＜0.05). Group B had a shorter OS time than Group C (P＜0.01), whereas Group A was not associated with a significant difference
in OS (P＞0.05). Conclusion: Serum AFP change may serve as a useful marker for clinical outcome and prognostic influence in patients
with hepatocellular carcinoma receiving systemic therapy. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
